Vox Sanguinis最新文献

{"title":"Platelet component safety in the era of new advancements in bacterial screening and pathogen reduction: A congress report of the 2024 ISBT Transfusion-Transmitted Infectious Diseases Working Party, Bacteria Subgroup.","authors":"Michel-Andrés García-Otálora, Carl McDonald, Jennifer Bearne, Bethany Brown, Anthea Cheng, Catherine Humbrecht, Pierre Tiberghien, Sandra Ramirez-Arcos","doi":"10.1111/vox.70053","DOIUrl":"10.1111/vox.70053","url":null,"abstract":"<p><strong>Background and objectives: </strong>High-income countries have successfully enhanced platelet component (PC) safety with the implementation of mitigation strategies including donor screening, skin disinfection, first aliquot diversion and PC bacterial screening or treatment with pathogen reduction technologies (PRT). This review discusses the experiences of several institutions with the adoption of bacterial screening methods and/or PRT and highlights residual safety risks.</p><p><strong>Materials and methods: </strong>Data from the American Red Cross (ARC), Australian Red Cross Lifeblood (Lifeblood), Canadian Blood Services (CBS), the Établissement Français du Sang (EFS) and National Health Service Blood and Transplant (NHSBT) were presented at the International Society of Blood Transfusion (ISBT) Congress, Transfusion-Transmitted Infectious Diseases meeting (Barcelona, June 2024) and were summarised in this report.</p><p><strong>Results: </strong>PC screening with the automated BACT/ALERT culture system began in 2004 in the ARC and CBS, while the system was adopted in 2008 and 2011 by Lifeblood and NHSBT, respectively. Implementation of PC treatment with the PRT INTERCEPT started in 2016, 2022, and 2006 in the ARC, CBS, and EFS, correspondingly.</p><p><strong>Conclusions: </strong>PC screening and PC treatment with PRT have significantly increased product safety. However, there are still residual safety risks posed by challenging organisms such as sporulated Bacillus spp. and toxin-producing Staphylococcus aureus.</p>","PeriodicalId":23631,"journal":{"name":"Vox Sanguinis","volume":" ","pages":"846-857"},"PeriodicalIF":1.6,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12390369/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144249780","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Understanding supply sustainability of plasma-derived medicinal products: Drivers and consequences of shortages.","authors":"Miriam Belmonte, Anna Albiero, Filip Callewaert, Julien Patris, Amanda Whittal","doi":"10.1111/vox.70052","DOIUrl":"10.1111/vox.70052","url":null,"abstract":"<p><p>Plasma-derived medicinal products (PDMPs), particularly immunoglobulins (Igs), are essential treatments for numerous diseases, often serving as the primary therapeutic option and playing a critical role in patient care. The human origin of these products, however, can lead to supply constraints due to a lack of plasma collection, market dynamics, regulatory challenges and manufacturing complexities. Many nations lack plasma self-sufficiency and often rely on the United States, which supplies approximately 70% of the world's plasma. This supply chain is vulnerable to disruptions, such as those caused by COVID-19. Additionally, plasma processing timelines are lengthy-Ig manufacturing takes 7-12 months compared with 2-3 months for biologics. Despite the global Ig market's projected growth from $13.36 billion to $24.98 billion between 2023 and 2032, plasma shortages persist. The European Medicines Agency anticipated shortages to affect 14 European countries in 2024. These factors can have significant implications for patients, with growing demand likely leading to supply challenges and forcing countries to prioritize certain indications in the face of shortages. Policy interventions may be needed to ensure the sustainable use of these products in treating immune-mediated disorders and related conditions. Exploring alternative treatments where possible could also mitigate the risk of shortages and maintain access to these life-saving therapies. This review examines the sustainability of PDMPs, focusing on drivers and consequences of shortages, insufficient plasma collection, vulnerability of the plasma supply chain and impacts on patients. A scoping literature research was conducted in PubMed, supplemented by internal knowledge and targeted web searches.</p>","PeriodicalId":23631,"journal":{"name":"Vox Sanguinis","volume":" ","pages":"754-764"},"PeriodicalIF":1.6,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12390372/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144151969","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Transfusion-associated graft-versus-host disease and purine analogues: What are we missing?","authors":"Chin Zhong Ng, Leigh Mosen, Christopher Corkery, Meredith Smith, Gustavo C Duarte","doi":"10.1111/vox.70047","DOIUrl":"10.1111/vox.70047","url":null,"abstract":"","PeriodicalId":23631,"journal":{"name":"Vox Sanguinis","volume":" ","pages":"858-860"},"PeriodicalIF":1.6,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144053501","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Breaking down barriers: Recruiting donors of African ancestry in Ireland.","authors":"Allison Waters, Niamh O'Flaherty, Ellen McSweeney, Safa Eltom, Barry Egan, Tor Hervig","doi":"10.1111/vox.70051","DOIUrl":"10.1111/vox.70051","url":null,"abstract":"<p><strong>Background and objectives: </strong>The diversity of the donor pool has an impact on blood provision for patients with inherited blood disorders, such as sickle cell anaemia. Many patients are critically dependent on red cell transfusions and due to uneven antigen distribution among different ethnic groups, they are at high risk of red cell alloimmunization. The aims of the present study were to understand the motivators and barriers to young Black Irish people donating blood, to explore the views of older Black individuals who were previously excluded but may now be eligible to donate following the recent changes to donor screening, and lastly, to make recommendations for future campaigns that appeal to the Irish Black community.</p><p><strong>Materials and methods: </strong>Online focus groups with people of African Ancestry living in Ireland were conducted (n = 6 focus groups, n = 47 participants). A semi-structured format was adopted. The focus group transcripts were analysed to identify the key themes expressed.</p><p><strong>Results: </strong>The main barriers to blood donation were (i) personal beliefs, (ii) distrust of healthcare organizations, (iii) previous negative donation experiences, (iv) a lack of basic information and (v) replacement donation. Motivators to donate blood included (i) altruism, (ii) Black representation, (iii) targeted information, (iv) helping the Black community and (v) building trust.</p><p><strong>Conclusion: </strong>Blood donor recruitment among the Irish Black community should be informed by an understanding of the varied attitudes to blood donation and the current social norms within Irish African communities. Ireland is a modern multicultural society and its blood donor pool should strive to reflect this diversity.</p>","PeriodicalId":23631,"journal":{"name":"Vox Sanguinis","volume":" ","pages":"765-775"},"PeriodicalIF":1.6,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12390370/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144132503","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Performance and acceptability of pre-donation screening and post-donation testing for hepatitis B infection in a resource-limited blood service.","authors":"Claude Tayou Tagny, Biseuleu Loic, Mathias Ndemanou, Fopa Diderot, Claude Maugard, Daniel Candotti, Georges Nguefack-Tsague, Syria Laperche","doi":"10.1111/vox.70058","DOIUrl":"10.1111/vox.70058","url":null,"abstract":"<p><strong>Background and objectives: </strong>Hepatitis B virus (HBV) is the virus transmissible by transfusion in Cameroon with highest prevalence. The benefit of pre-donation screening (PDS) versus post-donation testing (PDT) remains to be confirmed because of controversial results produced by the use of different methodologies. This study aims to compare the performance and blood donor acceptability with PDT strategy in the reduction of HBV risk.</p><p><strong>Materials and methods: </strong>A quasi-experimental study was conducted with two groups of participants. The consenting subjects chose prospectively and randomly either the PDS or the current PDT strategy. The donors included in the PDS group were screened for hepatitis B surface antigen (HBsAg) by using a World Health Organization (WHO)-prequalified HBsAg assay. The PDT strategy consisted of the routine double HBsAg testing with a combination of a rapid diagnostic test (RDT) and enzyme immuno assay (EIA). HBV confirmatory strategy combined testing for DNA detection and HBsAg neutralization assay. A questionnaire was designed to assess donor and staff satisfaction.</p><p><strong>Results: </strong>A total of 2528 blood donors were included in the study, of whom 1146 and 1382 went through PDS and PDT screening, respectively. The sensitivity of PDS and PDT was 100% and 96.4% (95% confidence interval [CI]: 93.1-100), respectively, and the specificity was 99.9% (95% CI: 99.3-100) for the two screening strategies. The overall acceptability score of the donor in the PDS group was 8.16 ± 1.61 versus 8.00 ± 1.55 in the PDT group (odds ratio [OR] 95% CI: 0.16 (0.04-0.28); p = 0.012).</p><p><strong>Conclusion: </strong>This study supports the benefits of safety and acceptability of the donor and also possible acceptable cost/benefit of the screening measure in the case of limited resources.</p>","PeriodicalId":23631,"journal":{"name":"Vox Sanguinis","volume":" ","pages":"812-819"},"PeriodicalIF":1.6,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144217098","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"An international survey on measures to prevent transfusion-transmitted infectious diseases-study results 1: Participation rates and the presence of laws, regulations, standards and best practices.","authors":"Galen Conti, Jay Epstein, Silvano Wendel, Claude Tayou Tagny, Antoine Lewin, Divjot Singh Lamba, Lesley Bust, Chancelar Kafere, Jean Stanley, Maria Roussakis, Hany Kamel, Roger Y Dodd, Susan L Stramer","doi":"10.1111/vox.70057","DOIUrl":"10.1111/vox.70057","url":null,"abstract":"<p><strong>Background and objectives: </strong>A global survey on blood safety measures to prevent transfusion-transmitted infectious diseases (TTIDs) was performed by examining variations in current usage. This analysis focuses on participation rates and the presence of relevant laws, regulations, standards and best practices for collection/processing of whole blood/components.</p><p><strong>Materials and methods: </strong>Distribution occurred between October 2023 and March 2024. States, provinces or cities within China and India were analysed as separate regions. Country/region (C/R) responses were categorized by World Bank income (WBI) levels: low- and lower middle-income (LLMI), upper middle-income (UMI) and high-income (HI). Consensus responses were used for multiple survey responses.</p><p><strong>Results: </strong>Responses from 131 individuals representing 74 C/Rs (65 countries, Hong Kong, counted separately, and 8 regions in China/India) were analysed. Affirmative responses for laws, regulations and standards were similar across WBI levels. Regulatory jurisdiction for blood/components was present in 96% of C/Rs (HI 100%, UMI 100%, LLMI 87%) and 94% at a national level when present (HI 100%, UMI 94%, LLMI 85%). All HI, UMI and 74% LLMI C/Rs reported routinely separating whole blood into components. HI C/Rs were more likely to screen for bacterial contamination, whereas periodic platelet quality control was more common in LLMI and UMI C/Rs. Pathogen reduction and universal leukocyte reduction were more common in HI C/Rs.</p><p><strong>Conclusion: </strong>Laws, regulations and standards for collection/processing of blood were consistent across WBI groups. Resource-intensive practices of blood component separation and use of advanced blood safety technologies were more variable, with less utilization in LLMI/UMI C/Rs.</p>","PeriodicalId":23631,"journal":{"name":"Vox Sanguinis","volume":" ","pages":"793-801"},"PeriodicalIF":1.6,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144226872","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Exploring tricine as a novel red cell cryopreservative: Lessons and future directions.","authors":"Thomas Bailey-Schmidt, Christine V Saunders, Chloë E George, Thomas G Scorer, Lynn M R McCallum, Tracey E Madgett","doi":"10.1111/vox.70088","DOIUrl":"https://doi.org/10.1111/vox.70088","url":null,"abstract":"<p><strong>Background and objectives: </strong>Cryopreservation allows for storage of red blood cells (RBCs) beyond the standard 35-day period. Current glycerol-based methods are labour-intensive and scale-limited in application. Tricine has been identified as a potential alternative cryoprotectant (CPA), demonstrating efficacy in sheep RBC. This study aims to evaluate the biocompatibility and efficacy of tricine in human RBC cryopreservation.</p><p><strong>Materials and methods: </strong>Human and sheep RBCs were exposed to varying concentrations of tricine (2.0-20.0% w/v) or glycerol (20.0-40.0% w/v). Biocompatibility was assessed via 24-h incubation at 4°C, while cryoprotective efficacy was evaluated following freezing in liquid nitrogen, storage at -80°C and thawing at 37°C. RBC recovery was assessed via spectrophotometric estimation of haemolysis.</p><p><strong>Results: </strong>Tricine was biocompatible, with <1% haemolysis in both species. When frozen, tricine provided significant protection against cryoinjury in sheep RBC, with maximal recovery at 8.0% w/v (42.17% ± 10.96% of RBC recovered). However, tricine lacked cryopreservative efficacy in human RBC, with post-thaw recovery rates on par with those seen following unprotected freezing. Even at the highest performing concentration (10.0% w/v), human RBC recovery remained low (16.08% ± 2.96%), highlighting the ineffectiveness of tricine in preserving human RBC integrity. Further analyses revealed greater hydrophilicity in sheep haemoglobin, which potentially influences freezing tolerance.</p><p><strong>Conclusion: </strong>Despite promising results within the ovine model, tricine lacks CPA efficacy for human RBC. Species differences in RBC physiology likely contribute to these discrepancies. These findings emphasize the need for rigorous model selection in cryopreservation research and further investigation into CPA mechanisms.</p>","PeriodicalId":23631,"journal":{"name":"Vox Sanguinis","volume":" ","pages":""},"PeriodicalIF":1.6,"publicationDate":"2025-07-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144761518","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comments on 'Use of computational biology to compare the theoretical tertiary structures of the most common forms of RhCE and RhD' and 'Prediction of the antigenic regions in eight RhD variants identified by computational biology'.","authors":"Aline Floch, Sunitha Vege, Christophe Tournamille, Julien Diharce, France Pirenne, Alexandre G de Brevern","doi":"10.1111/vox.70082","DOIUrl":"https://doi.org/10.1111/vox.70082","url":null,"abstract":"","PeriodicalId":23631,"journal":{"name":"Vox Sanguinis","volume":" ","pages":""},"PeriodicalIF":1.6,"publicationDate":"2025-07-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144733462","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Response to comments by Floch et al. on our papers on the use of computational biology to study RhCE and RhD structures.","authors":"Rocio Trueba-Gómez, Higinio Estrada-Juarez","doi":"10.1111/vox.70081","DOIUrl":"https://doi.org/10.1111/vox.70081","url":null,"abstract":"","PeriodicalId":23631,"journal":{"name":"Vox Sanguinis","volume":" ","pages":""},"PeriodicalIF":1.6,"publicationDate":"2025-07-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144733464","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Neocyte-enriched blood does not provide a survival advantage for red cells when compared to conventional filtered blood.","authors":"Adriaan Meyer, Heather Hendrickse, Glenda Mary Davison","doi":"10.1111/vox.70085","DOIUrl":"https://doi.org/10.1111/vox.70085","url":null,"abstract":"<p><strong>Background and objectives: </strong>Red blood cell (RBC) concentrates are stored at 1-6°C for up to 42 days, but storage lesions can lead to wastage. Pooled neocytes may extend RBC shelf-life, benefiting patients who require frequent transfusions. This study aimed to improve the longevity of stored RBCs by isolating neocytes and comparing the rate of haemolysis, biochemical changes and viability with filtered blood.</p><p><strong>Materials and methods: </strong>Thirty filtered units were processed. Neocytes were extracted and enriched with saline-adenine- glucose-mannitol. Both filtered and neocyte-enriched units were stored for 42 days. Samples were analysed every 14 days for RBC count, mean cell volume (MCV), mean cell haemoglobin concentration (MCHC), haemoglobin, sodium and supernatant haemolysis.</p><p><strong>Results: </strong>There was no significant difference in red cell count between filtered and neocyte-enriched units (p = 0.27). Both types showed increased mean corpuscular volume and decreased MCHC over the 42 days, with no significant differences observed (p ≥ 0.05). Sodium levels in the supernatant decreased while percentage supernatant haemolysis increased steadily in both units, albeit without significant differences (p ≥ 0.05). The haemoglobin remained stable for both unit types.</p><p><strong>Conclusion: </strong>Overall, neocyte-enriched blood did not demonstrate any longevity advantage compared to pre-stored leucocyte-reduced RBCs using the conventional manual collection method. These findings align with previous studies using various neocyte collection methods. Feasibility was highlighted as the main challenge, as many of these methods have proven too expensive and laborious.</p>","PeriodicalId":23631,"journal":{"name":"Vox Sanguinis","volume":" ","pages":""},"PeriodicalIF":1.6,"publicationDate":"2025-07-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144733463","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}